- Disease:Metabolic dysfunction-associated liver disease
- Substances:Ly3437943 SodiumTirzepatide
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Ly3437943 Sodium
- Sponsor:Eli Lilly & Co.
Metabolism and nutrition disorders – page 7
- 741 clinical trials
- 260 recruiting
- 237 conditions
- 26 countries
Conditions in this area
237 conditions with trials, the busiest first
Clinical trials in Metabolism and nutrition disorders
741 trials across Europe, recruiting first
Type of trial
Recruitment status
Quick filters
741 clinical trials
Recruiting
Hyperparathyroidism secondary
RecruitingRegistered drugNo placebo
Phase 3 Evaluation of Etelcalcetide for Secondary Hyperparathyroidism in Pediatric Patients with Chronic Kidney Disease on Hemodialysis
Registered drugNo placebo
- Disease:Hyperparathyroidism secondary
- Substances:Etelcalcetide
Countries:
Belgium
Belgium- Participants:0–17 years
- Substances:Etelcalcetide
- Sponsor:Amgen Inc.
Recruiting
Glycogen storage disease type II
RecruitingInvestigational
A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease
Investigational
- Disease:Glycogen storage disease type II
- Substances:–
Countries:Belgium
Belgium- Participants:18–64 years
- Sponsor:Shionogi B.V.
Recruiting
Endocrine ophthalmopathy
RecruitingInvestigational
Study of K1-70 compared to placebo for patients with active thyroid eye disease from Graves' disease
Investigational
- Disease:Endocrine ophthalmopathy
- Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST THYROTROPIN RECEPTOR
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST THYROTROPIN RECEPTOR
- Sponsor:Av7 Limited
Recruiting
Type IIa hyperlipidaemia
RecruitingInvestigational
A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
Investigational
- Disease:Type IIa hyperlipidaemia
- Substances:–
Countries:Belgium
Belgium- Participants:0–17 years
- Sponsor:Merck Sharp & Dohme LLC
Recruiting
Alpha-1 antitrypsin deficiency
RecruitingInvestigationalNo placebo
A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency
InvestigationalNo placebo
- Disease:Alpha-1 antitrypsin deficiency
- Substances:Human Alpha1-Proteinase Inhibitor
Countries:
Denmark
Denmark- Participants:18–64 years · 65+ years
- Substances:Human Alpha1-Proteinase Inhibitor
- Sponsor:Grifols Therapeutics LLC
Recruiting
Hyperkalaemia
RecruitingInvestigationalNo placebo
A study testing how well patiromer lowers high potassium levels in the blood in children under 12 years of age with hyperkalemia
InvestigationalNo placebo
- Disease:Hyperkalaemia
- Substances:Patiromer
Countries:Belgium
Belgium- Participants:0–17 years
- Substances:Patiromer
- Sponsor:Vifor Pharma Inc.
Recruiting
Diabetic neuropathy
RecruitingRegistered drug
A study testing capsaicin patches compared to placebo for patients with painful diabetic nerve damage to assess effects on nerve symptoms and nerve fibers
Registered drug
- Disease:Diabetic neuropathy
- Substances:Capsaicin
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Capsaicin
- Sponsor:Deutsche Diabetes Forschungsgesellschaft e.V.
Recruiting
Acute myocardial infarction+1
RecruitingRegistered drugNo placebo
Sodium-glucose cotransporter-2 inhibitor drug combination for patients with diabetes and heart attack to slow coronary artery disease progression
Registered drugNo placebo
- Disease:Acute myocardial infarctionDiabetes mellitus
- Substances:CanagliflozinDapagliflozin+1
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Canagliflozin
- Sponsor:Humanitas Mirasole S.p.A.
Recruiting
Porphyria non-acute
RecruitingInvestigationalNo placebo
Long-term study of bitopertin safety and effectiveness in patients with erythropoietic protoporphyria or X-linked protoporphyria
InvestigationalNo placebo
- Disease:Porphyria non-acute
- Substances:–
Countries:Belgium
Belgium- Participants:0–17 years · 18–64 years · 65+ years
- Sponsor:Disc Medicine Inc.
Recruiting
Diabetes mellitus+1
RecruitingRegistered drugNo placebo
A study of estradiol and progesterone treatment for blood sugar control in women with type 1 or type 2 diabetes during or after menopause
Registered drugNo placebo
- Disease:Diabetes mellitusMenopause
- Substances:EstradiolProgesterone, Micronised
Countries:
The Netherlands
The Netherlands- Participants:18–64 years
- Substances:Estradiol
- Sponsor:Amsterdam UMC Stichting
Recruiting
MELAS syndrome+2
RecruitingInvestigational
A study testing sonlicromanol in adults with genetically confirmed mitochondrial DNA 3243A>G variant causing mitochondrial disease
Investigational
- Disease:MELAS syndromeMitochondrial myopathy+1
- Substances:–
Countries:Denmark
Denmark- Participants:18–64 years
- Sponsor:Khondrion B.V.
Substances studied in this area
The therapies tested most often in Metabolism and nutrition disorders trials.